Epitalon, also known as Epithalon, has been studied in several biological and disease-related models, although the strength of evidence varies significantly depending on the specific condition. Direct research exists in areas involving retinal degeneration, reproductive cell aging, telomere biology, and animal aging, whereas no convincing evidence specific to Epitalon has been identified for fibromyalgia, ALS, or clinical use in dogs. [1–5]
Interest in searches regarding Epitalon often extends beyond longevity to include disease-specific topics such as fertility, fibromyalgia, amyotrophic lateral sclerosis (ALS), eye diseases, reproductive aging, and veterinary applications. Such interest is understandable, as Epitalon has been studied in the context of telomere biology, oxidative stress, mitochondrial function, retinal degeneration, gene regulation, and animal aging. However, a biologically plausible mechanism does not mean that every condition associated with oxidative stress, mitochondrial dysfunction, inflammation, or aging has actually been studied using Epitalon. [1]
The evidence also comes from very different levels of research. Some findings are based on human cell cultures, others on mouse or bovine reproductive models, a few on aging or disease experiments in rodents, and only a small number on human clinical trials or ex vivo studies using human material. This distinction is particularly important for disease-specific SEO content, because a mouse oocyte experiment should not be described as a human fertility study, a retinal cell experiment should not be presented as a treatment for diabetic retinopathy, and general neuroprotective mechanisms should not be extended to ALS without direct evidence.
What health conditions are associated with searches related to Epitalon?
Searches link Epitalon to fertility, fibromyalgia, ALS, retinal diseases, aging, cancer, cognitive function, and animal health, but these topics do not have equal support in scientific evidence. Retinal degeneration and the aging of reproductive cells have been the subject of direct experimental research, whereas for fibromyalgia, ALS, and clinical use in dogs, there is a lack of comparable, peer-reviewed evidence specific to Epitalon in the literature analyzed here. [1–5]
The broader literature on Epithalon is not centered around one specific disease. Epithalon was originally studied as part of Khavinson's short peptide research program and subsequently analyzed in relation to telomerase, telomere maintenance, chromatin regulation, melatonin, oxidative stress, lifespan, and several experimental organ-specific models. A 2025 review by Araj et al. summarizes this diverse evidence base and shows that the compound has been investigated primarily through in vitro approaches, animal studies, and mechanistic research rather than within a single conventional clinical development program. [1]
However, for a few health conditions, primary research does exist. One example is retinal degeneration. A 2002 publication involved Campbell rats with hereditary retinal degeneration as well as patients with degenerative retinal changes. The authors reported the preservation of retinal function in the animal model and a positive clinical effect in many of the studied patients. [2] However, the abstract available in PubMed does not contain sufficient details to consider these results as conclusive modern clinical evidence, because randomization, blinding, the structure of comparison groups, and full statistical analysis were not adequately described.
Reproductive biology is another area where there is direct research, although the evidence remains preclinical. A 2022 study analyzed post-ovulatory aging of mouse oocytes in vitro and reported effects regarding reactive oxygen species, mitochondrial function, spindle abnormalities, and apoptosis. [3] A separate 2025 study in cattle analyzed oocyte maturation and embryo development after thawing, and reported improvements in endpoints related to telomerase and embryonic development following exposure to Epitalon. [4] Neither of these studies addressed the treatment of human infertility.
Other health-related areas in the broader Epithalon literature include animal cancer models, retinal cell stress models, cognitive aging experiments in rats, melatonin regulation in monkeys, and cellular-level telomere studies. These results should remain tied to specific experimental models rather than being combined into a general claim that Epithalon „treats age-related diseases.”.
Has Epitalon been studied in the context of fertility?
Epitalon has been studied in reproductive biology, but not as an established human infertility treatment. The strongest direct evidence comes from in vitro mouse oocyte studies and a 2025 study on bovine embryo production. These experiments reported effects related to oocyte aging, mitochondrial function, telomerase-related biology, and embryo development, but have not demonstrated an effect on human pregnancy or fertility. [3,4]
The 2022 study by Yue and colleagues provides the most direct evidence regarding Epitalon in the context of reproductive system aging. The researchers used mouse oocytes in vitro to analyze post-ovulatory aging, a process in which oocyte quality gradually deteriorates after ovulation. Epitalon was added to the culture medium at a concentration of 0.1 mM, and the oocytes were evaluated at 6, 12, and 24 hours. [3]
Researchers noted lower levels of intracellular reactive oxygen species, fewer spindle abnormalities, and a more regular distribution of cortical granules after exposure to Epitalon. A higher mitochondrial membrane potential and a greater copy number of mitochondrial DNA were also observed, as well as lower markers of apoptosis after prolonged in vitro aging. [3] These results support the potential to influence the quality of aging mouse oocytes under laboratory conditions.
The study is significant for fertility research because oocyte quality plays a fundamental role in reproduction. However, it does not prove that Epitalon improves fertility in women. The experiment did not evaluate ovulation, fertilization rates, implantation, pregnancy, miscarriages, live births, or offspring outcomes in humans. It did not involve administering Epitalon to women or even to whole female mice attempting to become pregnant.
A study published in 2025 in Life Sciences extended these reproductive studies to in vitro bovine embryo production. Ullah and coworkers analyzed telomerase activity during oocyte maturation and embryo cryopreservation. Exposure to Epitalon was associated with improved oocyte maturation, increased blastocyst hatching after thawing, and changes in telomerase, reactive oxygen species, mitochondrial membrane potential, and gene expression-related endpoints. [4]
Research on cattle is of scientific importance because it analyzes oocytes, cumulus cells, and embryos within a reproductive biotechnology system. However, the production of bovine embryos is not equivalent to human infertility treatment. Interspecies differences, gamete biology, exposure, culture conditions, and reproductive physiology make direct clinical extrapolation inappropriate.
The evidence therefore supports a narrow conclusion: Epitalon has been experimentally investigated in the context of germ cell aging and embryonic developmental biology in non-human systems. It has not been clinically shown to improve fertility in humans.
Claims that Epitalon „increases female fertility,” „improves IVF success,” „reverses ovarian aging,” or „increases pregnancy rates” require direct human reproductive studies, which are currently lacking in the analyzed evidence.
Has Epitalon been studied in the context of fibromyalgia?
Neither in the provided set of studies nor in the targeted searches of peer-reviewed literature conducted for this article was any direct, Epitalon-specific study regarding fibromyalgia identified. Although fibromyalgia involves pain, sleep disturbances, fatigue, and altered neurobiological signaling, the overlap of these mechanisms does not prove that Epitalon has been studied or has demonstrated efficacy in this condition.
Fibromyalgia is a chronic disorder characterized by widespread pain and frequently co-occurring symptoms such as fatigue, sleep disturbances, cognitive issues, and increased pain sensitivity. Because Epitalon appears in research concerning melatonin, oxidative stress, neuroendocrine regulation, and the biology of aging, theoretical links can be pointed out between some of Epitalon's mechanisms and symptoms associated with fibromyalgia.
This type of mechanism overlap does not constitute sufficient evidence.
For example, Epitalon was studied in relation to melatonin production in pineal cell systems and in older non-human primates. It also affected oxidative stress markers in several experimental models. These results do not prove a reduction in generalized pain, an improvement in tender point sensitivity, better physical functioning, or lower fibromyalgia symptom assessment scores in humans.
A direct study of fibromyalgia would have to include participants with a specific diagnosis and evaluate clinically relevant outcomes, such as pain intensity, physical functioning, sleep quality, fatigue, cognitive symptoms, and quality of life. Ideally, such a study should have a randomized, placebo-controlled design.
No Epitalon study of this type was identified in the evidence analyzed here.
Therefore, Epitalon cannot be described as a fibromyalgia treatment, pain therapy, or clinically validated intervention in fibromyalgia solely on the basis of general neuroendocrine or oxidative stress-related mechanisms.
Has Epitalon been studied in the context of ALS?
In the evidence analyzed for this article, no direct peer-reviewed clinical or preclinical studies specifically evaluating Epitalon in amyotrophic lateral sclerosis were identified. However, Epitalon has neurobiological and oxidative stress studies, including research on human stem cells and animals, but these results should not be translated into claims regarding the treatment of ALS or the protection of motor neurons. [1,5]
ALS is a progressive neurodegenerative disease involving the degeneration of upper and lower motor neurons. Its biology encompasses multiple processes such as protein aggregation, excitotoxicity, mitochondrial dysfunction, RNA processing abnormalities, inflammation, and oxidative stress. Because Epitalon has been studied in some of these broader biological areas, particularly in the context of oxidative stress and gene regulation, it might seem superficially relevant.
However, the key point is that biological significance is not the same as disease-specific evidence.
The 2020 Epitalon study utilized human gingival mesenchymal stem cells and reported increased expression of neuronal differentiation markers, including Nestin, GAP43, β-tubulin III, and Doublecortin. Molecular modeling in the same study suggested interactions involving histone H1 variants. [5] This provides interesting mechanistic evidence regarding neuronal differentiation pathways in cultured cells.
However, this is not an ALS model.
The cells were not motor neurons obtained from individuals with ALS, the experiment did not model typical genetic abnormalities associated with ALS, and it did not evaluate motor neuron survival, neuromuscular function, disease progression, or clinical outcomes.
Epitalon has also been studied in animal and cellular models involving oxidative stress, but oxidative stress occurs in many diseases. A compound affecting reactive oxygen species in one cell type does not automatically become a treatment for every disorder in whose pathology oxidative stress participates.
Therefore, claims that Epitalon slows the progression of ALS, protects motor neurons, improves muscle function, or extends survival in ALS remain unsupported without direct ALS-specific evidence.
Broader neurobiological mechanisms are discussed in the article Epitalon Mechanism of Action: How Does the Peptide Work?
Has Epitalon been studied in dogs?
Neither in the provided evidence base nor in the targeted searches conducted for this article was any peer-reviewed interventional study of Epitalon in dogs identified. Epitalon has been studied in several other animal species, but results obtained in mice, rats, cattle, primates, or cell cultures cannot confirm benefits regarding lifespan, healthspan, cognitive function, or diseases in dogs.
This distinction is important because animal studies are not automatically studies on dogs.
Epitalon has an extensive literature on animal research. The studies included mice, rats, fruit flies, rhesus macaques, and more recently also bovine reproductive systems. In these experiments, lifespan, spontaneous tumors, melatonin rhythms, memory, oxidative stress, retinal degeneration, and reproductive cell aging, among other things, were evaluated.
Dogs differ physiologically from each of these experimental models.
The evidence base for dogs should ideally include species-specific pharmacokinetics, metabolism, exposure, safety, immune responses, organ toxicity, and clinically relevant veterinary outcomes. For aging-related claims, appropriate endpoints should also include mobility, cognitive function, frailty syndrome, disease incidence, quality of life, healthspan, or survival in appropriately designed canine studies.
No data specific to dogs of this type were identified in the reviewed peer-reviewed literature.
Therefore, the claims that Epitalon „extends the lifespan of dogs,” „improves cognitive aging in dogs,” „reverses aging in dogs,” or „has proven safety in older dogs” should not be presented as established evidence.
The existence of commercial veterinary discussions regarding Epitalon also does not replace peer-reviewed interventional studies in dogs.
Studies on mice or rats can provide scientific justification for testing a given compound in dogs, but they cannot independently confirm its veterinary efficacy or safety.
What actual research results on Epitalon regarding specific diseases exist?
There are studies on Epitalon regarding specific diseases, but they focus on a limited number of experimental areas rather than all conditions associated with internet searches. Retinal degeneration has both animal data and limited older human data, reproductive system aging has data from studies on mice and cattle, and there are additionally several cancer or oxidative stress-related models, while many other conditions have not been directly studied. [1–7]
Retinal degeneration is one of the most striking examples of direct research into a specific disease. A study published in 2002 in *Neuro Endocrinology Letters* analyzed congenital retinal degeneration in Campbell rats and presented observations regarding patients with degenerative retinal changes. [2] According to the abstract in PubMed, Epitalon improved the bioelectrical and functional activity of the retina in an animal model and produced an effect that the authors described as a positive clinical effect in treated patients.
This result is frequently cited, but it requires careful interpretation. The abstract does not contain sufficient methodological information to determine the strength of clinical evidence according to modern standards. The number of patients, allocation procedures, comparison groups, blinding, and definitions of endpoints were not adequately described in the abstract. Therefore, this result is better characterized as an older clinical signal requiring modern confirmation, rather than as proof that Epitalon treats retinitis pigmentosa.
A newer retinal study concerned a different condition and a completely different level of evidence. In 2025, Gatta and colleagues used human retinal pigment epithelium ARPE-19 cells exposed to high glucose concentration as an in vitro model related to diabetic retinopathy. Epitalon improved cell migration and reduced several changes associated with oxidative stress and fibrosis. [6]
This constitutes evidence derived from research on human cells, rather than from the treatment of individuals with diabetic retinopathy.
Cancer research represents another area related to disease, although the results also depend on the specific experimental model. Several older studies in rodents reported a reduction in certain cancer outcomes, whereas at least one bladder carcinogenesis model showed no inhibitory effect of Epitalon. A newer 2025 study on telomeres in human cells also demonstrated telomere elongation in breast cancer cell lines via alternative lengthening of telomeres, which highlights why telomere biology cannot be interpreted as unequivocally beneficial. [7]
These examples show a basic principle regarding content about Epitalon and specific conditions: the disease, model, species, and measured endpoint should remain linked to each specific result.
How should preclinical results regarding specific diseases be interpreted?
Preclinical disease-specific results show that Epitalon affected a biological process in a specific laboratory model; they do not prove that it cures the corresponding disease in humans. Interspecies differences, artificial experimental conditions, exposure levels, disease complexity, and pharmacokinetics can prevent promising cellular or animal results from translating into clinical benefit.
A preclinical experiment answers a narrower question than a clinical trial.
For example, a 2022 study on mouse oocytes shows that Epitalon altered oxidative stress, mitochondrial function, and structural markers in aging mouse oocytes in culture. [3] It does not prove improved fertility in women.
A 2025 study on bovine embryos demonstrates effects during in vitro production of cattle embryos. [4] It does not prove improved IVF outcomes in humans.
A 2025 retinal cell study shows that Epitalon affected migration, oxidative stress markers, and fibrosis-related pathways in cultured ARPE-19 cells exposed to high glucose. [6] It does not confirm the treatment of diabetic retinopathy.
The same distinction applies to telomere research. Early studies on human fibroblasts showed telomerase activation and telomere lengthening, while a newer 2025 study confirmed telomere-related effects in several human cell lines. [7,8] The use of human cells makes these findings relevant to human biology, but studies on human cells still differ from clinical trials in humans.
Disease models are deliberately simplified. Researchers can isolate a single pathological process, expose cells to a specific stressor, or use genetically selected animals. Individuals with a disease differ in their genetics, disease stage, medications taken, comorbidities, and tissue environment, which cannot be fully replicated in laboratory systems.
Therefore, preclinical results can be more accurately described using phrases such as:
„Epitalon reduced oxidative stress in this model.”
„Epitalon was associated with the improvement of oocyte quality markers in mouse cells.”
„Epitalon altered the response of retinal cells under high glucose conditions.”
They should not be transformed into statements such as:
„Epitalon cures infertility.”
„Epitalon reverses diabetic retinopathy.”
„Epitalon protects against neurological diseases.”
These are clinical claims requiring direct clinical evidence.
Why should a research interest not be presented as clinical efficacy?
Research interest means that a compound has yielded results deemed worthy of further study; clinical efficacy, on the other hand, requires evidence that it significantly improves patient health outcomes. The literature on Epitalon contains many biologically interesting results, but most of them come from cellular studies, animal models, or limited older clinical reports, which is why the overall evidence base does not support broad claims regarding disease treatment. [1]
This distinction is particularly important in the case of Epithalon, as this molecule is associated with several pathways involved in many diseases. Telomere shortening is linked to aging and numerous chronic diseases. Oxidative stress occurs in cardiovascular, neurological, metabolic, and inflammatory diseases. Mitochondrial dysfunction is significant for reproduction, neurodegeneration, muscle diseases, and aging. Melatonin and circadian rhythm disorders are associated with sleep disorders and many chronic diseases.
A peptide affecting one of these pathways may therefore seem relevant to many different disorders.
However, a connection to a specific biological pathway does not imply effectiveness in treating every disease in which this pathway is involved.
An example is telomerase. Epitalon increased telomerase activity or telomere length in cultured human cells. [7,8] This demonstrates a cellular effect. It does not prove the prevention of cardiovascular disease, neurodegeneration, infertility, fibromyalgia, or general aging.
The same applies to oxidative stress. Epitalon reduced the level of reactive oxygen species in mouse oocytes and retinal cell models. [3,6] These results do not confirm that systemic administration produces an equivalent antioxidant effect in patients with diseases unrelated to these models.
Clinical efficacy typically requires controlled human trials using patient-relevant outcomes. Depending on the condition, relevant outcomes may include pregnancy and live birth rates for fertility, pain and physical function in fibromyalgia, disease progression and survival in ALS, visual function in retinal diseases, or quality of life and survival in the case of animal aging.
Without such data, the scientifically correct position is not to state that Epitalon „does not work” in every unstudied condition. The correct position is to state that its efficacy has not been established.
What clinical evidence in humans exists for individual health conditions?
Clinical evidence regarding Epitalon in humans is much narrower than the preclinical literature. The most prominent publication concerning a specific condition is an older report on retinitis pigmentosa, while much of the remaining human-related evidence comes from cultured human cells, ex vivo tissues, or limited neuroendocrine observations rather than modern randomized clinical trials targeting specific diseases. [1,2,7,8]
The publication regarding the retina is relevant because PubMed classifies it as a clinical study, and its abstract clearly describes the treatment of patients with degenerative retinal changes. [2] However, the reporting of methodology is incomplete by modern standards, so this study should not be interpreted as conclusive evidence of efficacy.
Other frequently cited „human studies” on Epitalon are actually laboratory experiments using material of human origin.
The classic 2003 study by Khavinson, Bondarev, and Butyugov involved exposing human fetal fibroblasts to Epithalon and demonstrated the induction of the catalytic component of telomerase, telomerase activity, and telomere elongation. [8]
The 2025 study by Al-Dulaimi used normal human fibroblast and mammary epithelial cell lines along with two human breast cancer cell lines. The researchers observed telomere elongation through different mechanisms depending on the cell type. [7] These are human cells, but no person was administered Epitalon.
Ex vivo studies using human material also included cultured lymphocytes obtained from elderly individuals and demonstrated an effect on chromatin organization. Studies of this type can help in explaining possible mechanisms, but they do not prove a treatment for the disease.
Therefore, articles discussing Epitalon in relation to a specific health condition should distinguish whether the compound was actually studied in patients with that condition.
Regarding fertility, fibromyalgia, ALS, and dogs, the answer based on the evidence analyzed here is: no.
Evidence by condition in brief
| Condition or field of study | Best identified evidence regarding Epitalon | What can be reasonably stated? |
|---|---|---|
| Human fertility | No direct clinical trial was identified | No benefits for human fertility have been established. |
| Oocyte aging | Mouse oocytes in vitro [3] | Epitalon influenced oxidative stress, mitochondria, and oocyte quality markers in mouse cells. |
| Embryonic development | In vitro production of bovine embryos [4] | An improvement in bovine oocyte/embryo endpoints was noted; this does not constitute evidence regarding human IVF. |
| Fibromyalgia | No direct study was identified | An evidence-based claim of efficacy cannot be formulated. |
| ALS | No direct ALS study was identified | General neurobiological findings cannot be transferred to ALS. |
| Psy | No peer-reviewed intervention study in dogs has been identified | Efficacy in dogs, impact on lifespan, and safety remain unestablished. |
| Retinitis pigmentosa | Rat model + older human clinical report [2] | A clinical signal has been reported, but contemporary controlled confirmation is lacking. |
| Biology of diabetic retinopathy | Human retinal cell line under high glucose conditions [6] | Significant cellular effects were noted; this was not a clinical treatment study. |
| Telomere shortening | Human cell cultures [7,8] | Epitalon can affect telomere maintenance mechanisms in vitro. |
| Cancers | Numerous animal/cell models with mixed results | No claims have been established regarding the treatment or prevention of cancer in humans. |
| Overall longevity | Animal models | No extension of human life has been demonstrated. |
Frequently asked questions about Epitalon and health conditions
Is Epitalon used in the context of fertility?
Epitalon has been studied in mouse oocytes and bovine embryo production systems, where researchers noted effects related to oxidative stress, mitochondrial function, telomerase-related biology, and developmental endpoints. [3,4] No controlled human fertility study has demonstrated improvements in fertilization rates, IVF success, implantation, pregnancy, or live birth.
Can Epitalon improve egg cell quality?
A 2022 in vitro study of mouse oocytes reported an improvement in structural and mitochondrial markers in post-ovulatorily aged oocytes after exposure to Epitalon. [3] This supports a preclinical effect on markers of mouse oocyte quality, but does not prove that Epitalon improves human egg quality or fertility.
Has Epitalon been studied in the context of fibromyalgia?
No direct study of Epitalon regarding fibromyalgia was identified in the evidence reviewed for this article. Studies involving melatonin, oxidative stress, and neuroendocrine biology do not support pain reduction or clinical efficacy in fibromyalgia.
Has Epitalon been studied in the context of ALS?
No direct peer-reviewed studies regarding ALS have been identified. Epitalon has neurobiological and gene regulation studies utilizing cultured cells, but these experiments were not ALS models and do not demonstrate motor neuron protection or slowing of ALS progression in humans. [5]
Has Epitalon been used in dogs?
There are commercial discussions on this topic, but no peer-reviewed interventional studies in dogs were identified in the literature analyzed here. Results obtained in mice, rats, cattle, or non-human primates cannot confirm canine lifespan extension, healthspan improvement, veterinary dosing, or long-term safety.
Has Epitalon been studied in humans?
Yes, although evidence regarding humans remains limited. An older clinical publication included patients with retinal degeneration, while other human-related studies used cultured fibroblasts, epithelial cells, or ex vivo lymphocytes. [2,7,8] These different types of evidence should not be considered equivalent.
Does Epitalon treat retinitis pigmentosa?
An older publication from 2002 reported positive effects in Campbell rats and patients with retinal degeneration. [2] The result is clinically interesting, but the publication does not provide the detailed, contemporary evidence from randomized trials required to recognize Epitalon as a treatment for retinitis pigmentosa.
Does Epitalon have proven efficacy in age-related diseases?
No. Epitalon has been studied in numerous age-related biological processes and disease models, but there is no widespread clinical evidence showing that it treats age-related diseases as a category. Each condition requires its own controlled clinical evidence.
Limitations of evidence for Epitalon in individual diseases
The greatest limitation is the uneven degree of directness of the evidence. The scope of searches is much broader than the experimental literature. Epitalon is searched in connection with fertility, fibromyalgia, ALS, cancer, retinal diseases, and animal aging, but only some of these topics have direct research on Epitalon.
Another limitation is the frequent equating of human cells with human clinical evidence. A fibroblast or retinal epithelial cell may be of human origin, but exposing these cells to AEDG in culture is fundamentally different from administering the peptide to a patient and measuring disease outcomes.
Thirdly, the evidence regarding reproduction remains non-human. A 2022 mouse oocyte study and a 2025 bovine embryo study are valuable mechanistic and reproductive biotechnology experiments, but neither supports claims regarding human fertilization, ovarian reserve, IVF efficacy, or pregnancy. [3,4]
Fourthly, older human clinical reports require careful interpretation. The publication concerning retinitis pigmentosa provides an important human signal, but its abstract does not describe many of the methodological features expected of contemporary clinical studies. [2]
Fifth, the lack of evidence must also be described precisely. Failing to identify a study regarding fibromyalgia, ALS, or dogs does not prove that Epitalon could never exert an effect in these contexts. It means that clinical efficacy currently remains undetermined.
Finally, Epitalon's activity across multiple biological pathways particularly facilitates overextrapolation. Telomerase, oxidative stress, mitochondria, gene regulation, and melatonin are involved in many conditions, but pathway overlap provides a rationale for further research rather than proof of treatment efficacy.
Applications
Epitalon has been studied in several health-related contexts, but available evidence does not support presenting it as a general treatment for age-related or chronic diseases. The strongest research on specific conditions includes an older study on retinal degeneration, mouse germ cell aging, bovine embryo development studies, and several disease-relevant cell or animal models. [2–6]
Regarding fertility, the evidence remains preclinical and is limited to mouse oocytes and bovine reproductive systems. Regarding fibromyalgia, no direct studies specific to Epitalon have been identified. Regarding ALS, no direct evidence specific to this disease has been identified despite broader neurobiological research. Regarding dogs, no peer-reviewed interventional study regarding this species was identified in the analyzed literature.
A scientifically sound interpretation should therefore be specific to each condition: every result must be linked to an exact research model, cellular and animal data should remain separate from human clinical evidence, and mechanistic significance should not be transformed into claims regarding clinical efficacy.
Disclaimer
The article is for educational and scientific-informational purposes only and does not constitute medical advice, diagnosis, treatment guidelines, veterinary advice, or a recommendation for the use of Epitalon. Epitalon/Epithalon (AEDG; Ala-Glu-Asp-Gly) remains an experimental compound in the health contexts discussed here. Preclinical results concerning mouse oocytes, bovine embryos, retinal cells, or other experimental systems should not be interpreted as proof of efficacy in humans or animals. Evidence regarding humans remains limited, and clinical efficacy has not been established for fibromyalgia, ALS, human fertility, or canine longevity.
References
[1] Araj, S. K., Brzezik, J., Mądra-Gackowska, K., & Szeleszczuk, Ł. (2025). Overview of Epitalon—Highly bioactive pineal tetrapeptide with promising properties. International Journal of Molecular Sciences, 26(6), 2691.
https://doi.org/10.3390/ijms26062691
[2] Khavinson, V., Razumovsky, M., Trofimova, S., Grigorian, R., & Razumovskaya, A. (2002). Pineal-regulating tetrapeptide Epitalon improves eye retina condition in retinitis pigmentosa. Neuro Endocrinology Letters, 23(4), 365–368.
https://pubmed.ncbi.nlm.nih.gov/12195242/
[3] Yue, X., Liu, S.-L., Guo, J.-N., Meng, T.-G., Zhang, X.-R., Li, H.-X., Song, C.-Y., Wang, Z.-B., Schatten, H., Sun, Q.-Y., & Guo, X.-P. (2022). Epitalon protects against post-ovulatory aging-related damage of mouse oocytes in vitro. Aging, 14(7), 3191–3202.
https://doi.org/10.18632/aging.204007
[4] Ullah, S., Haider, Z., Perera, C. D., Lee, S. H., Idrees, M., Park, S., & Kong, I.-K. (2025). Epitalon-activated telomerase enhance bovine oocyte maturation rate and post-thawed embryo development. Life Sciences, 362, 123381.
https://doi.org/10.1016/j.lfs.2025.123381
[5] Khavinson, V., Diomede, F., Mironova, E., Linkova, N., Trofimova, S., Trubiani, O., Caputi, S., & Sinjari, B. (2020). AEDG peptide (Epitalon) stimulates gene expression and protein synthesis during neurogenesis: Possible epigenetic mechanism. Molecules, 25(3), 609.
https://doi.org/10.3390/molecules25030609
[6] Gatta, M., Dovizio, M., Milillo, C., Ruggieri, A. G., Sallese, M., Antonucci, I., Trofimov, A., Khavinson, V., Trofimova, S., Bruno, A., & Ballerini, P. (2025). The antioxidant tetrapeptide Epitalon enhances delayed wound healing in an in vitro model of diabetic retinopathy. Stem Cell Reviews and Reports, 21(6), 1822–1834.
https://doi.org/10.1007/s12015-025-10911-x
[7] Al-Dulaimi, S., Thomas, R., Matta, S., & Roberts, T. (2025). Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology, 26(5), Article 178.
https://doi.org/10.1007/s10522-025-10315-x
[8] Khavinson, V. K., Bondarev, I. E., & Butyugov, A. A. (2003). Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine, 135(6), 590–592.
https://doi.org/10.1023/A:1025493705728